Mymetics Corp. is a vaccine company, which focuses on the research and development of next generation vaccines for infectious and life disabling diseases. The company is headquartered in Epalinges, Vaud and currently employs 8 full-time employees. The firm is focused on developing vaccines for infectious diseases. The firm has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Follow-Up Questions
Mymetics Corp (MYMX)의 PER은 얼마입니까?
Mymetics Corp의 PER은 0입니다
MYMX 주식의 가격 성능은 어떻습니까?
MYMX의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Mymetics Corp의 주요 사업 주제나 업종은 무엇입니까?
Mymetics Corp은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
